BernstenC.AnderssonK.GariepyY.SimoensS. (2010) A comparative analysis of remuneration models for pharmaceutical professional services. Health Policy95(1): 1–9.
2.
GoldbergP. K. (2010) Alfred Marshall lecture: Intellectual property rights protection in developing countries: The case of pharmaceuticals. Journal of the European Economic Association8(2/3): 326–353.
3.
WymerW. (2010) Consumer perceptions of prescription drug websites: A pilot study. Health Marketing Quarterly27(2): 173–194.
4.
StyhreA.WikmalmL.OlillaS.RothJ. (2010) Garbage-can decision making and the accommodation of uncertainity in new drug development work. Creativity & Innovation Management19(2): 134–146.
5.
HughesB.WarehamJ. (2010) Knowledge arbitrage in global pharma: A synthetic view of absorptive capacity and open innovation. R&D Management40(3): 324–343.
6.
CoxA. D.CoxD.MantelS. P. (2010) Consumer response to drug risk information: The role of positive effect. Journal of Marketing74: 31–44.
7.
SabatierV.MangematinV.RouselleT. (2010) From recipe to dinner. Long Range Planning43: 431–447.
8.
CoffR. W. (2010) The coevolution of rent appropriation and capability development. Strategic Management Journal31(7): 711–733.
9.
LeeR. P.JohnsonJ. L. (2010) Managing multiple facets of risk in new product alliances. Decision Sciences41(2): 271–300.
10.
FestelG.SchickerA.BoutellierR. (2010) Performance improvement in pharmaceutical R&D through new outsourcing models. Journal of Business Chemistry7(2): 89–96.
11.
AherneM.MackenzieS. B.PodsakoffP. M.MathieuJ. E.LamS. K. (2010) The role of consensus in sales team performance. Journal of Marketing Research47: 458–469.
12.
SiedlokF.SmartP.GuptaA. (2010) Convergence and reorientation via open innovation: The emergence of nutraceuticals. Technology Analysis & Strategic Management22(5): 571–592.
13.
SternitzkeC. (2010) Knowledge sources, patent protection, and commercialization of pharmaceutical innovations. Research Policy39(6): 810–821.
14.
ZapataJ. C.ReklaitisG. V. (2010) Valuation of project portfolios: An endogenously discounted method. European Journal of Operational Research206(3): 653–666.
15.
KanavosP.VandorosS. (2010) Competition in prescription drug markets: Is parallel trade the answer?. Managerial & Decision Economics31(5): 325–338.
16.
HemphillT. (2010) Extraordinary pricing of orphan drugs: Is it a socially responsible strategy for the US pharmaceutical industry?. Journal of Business Ethics94(2): 225–242.
17.
CromelinD. (2010) Pharmaceutical sciences in 2020. Nature Reviews: Drug Discovery9: 99–100.
18.
PaulS. M. (2010) How to improve R&D productivity: The industry's grand challenge. Nature reviews. Drug Discovery9: 203–214.
19.
StrausS. (2010) Pharma embraces open source models. Nature Biotechnology28: 631–634.
20.
CarlsonJ. J. (2010) Linking payment to health outcomes: A taxonomy and examination of performance-based reimbursement schemes between healthcare payers and manufacturers. Health Policy96(3): 179–190.
21.
TaewooY., Efficiency and its determinants in pharmaceutical industries: Ownership, R&D and scale economy. Applied Economics42(17): 2217–2241.
